DMT Clinical Trials 2025: Breakthrough Research on Depression Treatment

The landscape of psychiatric medicine is shifting faster than most observers anticipated. After nearly 50 years in regulatory purgatory, psychedelic compounds are re-entering clinical research with methodological rigour and, increasingly, regulatory momentum. Among them, N,N-Dimethyltryptamine occupies a uniquely interesting position: it is simultaneously one of the most intense psychedelic experiences known, one of the shortest-lasting, and one of the few compounds that appears to exist naturally within the human body.

This article traces the scientific history of DMT, the current clinical trial landscape as of 2025-2026, the neurological mechanisms that explain its therapeutic potential, and the broader context of what psychedelic medicine means for mental health care. It also addresses the spiritual dimensions of DMT experience that clinical researchers are increasingly taking seriously as therapeutically relevant rather than incidental.

This is reporting on legal clinical science, not an endorsement of recreational use. DMT remains a Schedule I substance in the United States, a controlled substance under the UN Convention on Psychotropic Substances, and similarly regulated in most jurisdictions. The research discussed here takes place under strict regulatory oversight with medical professionals.

What is DMT?

The Chemistry

N,N-Dimethyltryptamine (DMT) is a tryptamine compound with the molecular formula C12H16N2. It shares the basic tryptamine scaffold with serotonin, melatonin, psilocybin, and the hormone melatonin, all of which are deeply embedded in mammalian neurobiology. DMT is biosynthesised in the body from tryptophan through a two-step enzymatic pathway: tryptophan decarboxylase converts tryptophan to tryptamine, which is then methylated twice by the enzyme indolethylamine-N-methyltransferase (INMT) to produce DMT.

The Endogenous Puzzle

The fact that DMT is found in human blood, urine, and cerebrospinal fluid has been documented since the 1970s but remains biologically puzzling. What is it doing there? The concentrations found endogenously are far below the threshold for psychedelic effects. However, Strassman and others have speculated about its possible roles: as a modulator of the sigma-1 receptor (involved in neuroplasticity and neuroprotection), as a component of near-death physiology, or as part of dreaming. A 2019 study by Dean et al. at the University of Michigan demonstrated that DMT levels in rat cortex rise significantly at cardiac arrest, lending tentative support to theories about DMT's involvement in end-of-life neurological events.

Plant Sources

DMT occurs in over 50 plant species across multiple botanical families. The most clinically relevant include Psychotria viridis (chacruna), used in traditional ayahuasca preparations; Mimosa hostilis (jurema) used in Brazilian traditions; and Anadenanthera peregrina, source of cohoba snuff used in indigenous Antillean ceremonies. Synthetic DMT, used in clinical trials, is chemically identical to plant-derived DMT.

Rick Strassman and the History of DMT Research

The Research Hiatus

Following the Controlled Substances Act of 1970, which scheduled DMT as Schedule I (high abuse potential, no accepted medical use), human research with psychedelics effectively ceased in the US for nearly two decades. The prohibition was not based on a clinical evidence base for harms at therapeutic doses; it was a policy decision in the context of the cultural politics of the late 1960s. By the 1980s, a small number of researchers began the bureaucratic process of reopening the inquiry.

Strassman's UNM Studies (1990-1995)

Rick Strassman, a clinical psychiatrist and professor at the University of New Mexico, received DEA Schedule I researcher status in 1990 and conducted the first federally approved psychedelic research on humans in the United States since the 1970s. Over five years, he administered intravenous DMT to 60 volunteers across approximately 400 sessions. His dose-finding and phenomenological studies documented DMT's effects systematically for the first time in a controlled setting.

Strassman's published findings and his 2001 book DMT: The Spirit Molecule (which became a documentary in 2010) documented several striking phenomenological patterns: the extraordinary speed of onset (seconds for IV DMT), the consistent presence of apparently autonomous non-human entities in many experiences, the frequency of mystical and near-death-type experiences, and the generally positive lasting psychological effects of participants. The research was scientifically descriptive; Strassman explicitly avoided claims about the metaphysical reality of the entities or experiences.

The Gap Between Strassman and the Current Wave

Strassman's work was not followed by immediate clinical development. The regulatory and funding environment remained hostile. What changed the landscape was the success of psilocybin and MDMA research from the mid-2000s onward, work by groups at Johns Hopkins, NYU, and Imperial College London that began generating positive Phase 2 data and significant public and investor attention. This created the conditions in which DMT-specific clinical development could begin.

The 2025 Clinical Trial Landscape

Small Pharma: SPL026

The most advanced DMT clinical programme globally as of 2025 belongs to Small Pharma, a UK-based psychedelic pharmaceutical company. Their lead compound, SPL026 (a synthetic N,N-DMT formulation designed for intravenous administration), has been studied in combination with psychotherapy for major depressive disorder (MDD). Small Pharma completed a Phase 1 safety study and a Phase 2a proof-of-concept trial.

The Phase 2a results, published in 2024, reported clinically meaningful antidepressant responses in a significant proportion of participants, with reductions in MADRS (Montgomery-Asberg Depression Rating Scale) scores sustained at follow-up assessments up to 2 weeks post-treatment. The company has described the session experience as manageable and the acute cardiovascular effects as within acceptable parameters. Detailed Phase 2b trial planning was underway as of late 2025.

Algernon Pharmaceuticals

Algernon Pharmaceuticals, a Canadian company, has explored DMT in the context of both depression and stroke rehabilitation. Their research interest in stroke recovery is particularly interesting: preclinical data suggested DMT may stimulate neuroplasticity in ways beneficial for post-stroke recovery, a mechanism distinct from the antidepressant pathway. As of 2025, Algernon's DMT programme had encountered clinical setbacks requiring design refinement, but the company remained active in the space.

Academic Centres and Investigator-Led Studies

Independent of pharmaceutical sponsors, academic centres including Imperial College London (home of the Centre for Psychedelic Research led by Robin Carhart-Harris before his move to UCSF), the Beckley Foundation, and several European academic medical centres have conducted investigator-led DMT studies. Imperial College's open-label work with IV DMT contributed to the understanding of DMT's EEG signature and its relationship to the default mode network. These studies form the mechanistic foundation that pharmaceutical trials build on.

The Regulatory Status of DMT Trials

Clinical trials with Schedule I substances in the US require both FDA approval of the trial protocol and DEA researcher licensing. The regulatory pathway is arduous but navigable; dozens of psilocybin and MDMA trials have demonstrated this. In the UK, DMT clinical research operates under Home Office licensing. Australia, which became the first country to formally legalise psychedelic-assisted therapy (for MDMA and psilocybin) in 2023, represents the leading edge of regulatory integration of psychedelic medicines into mainstream healthcare.

How DMT Differs from Psilocybin and Ketamine

Duration as a Defining Variable

The practical clinical advantage of DMT is its duration. Intravenous DMT produces a full psychedelic experience lasting approximately 15-30 minutes, compared to 4-6 hours for psilocybin and 6-8 hours for MDMA. A single therapist can see multiple patients in a day at a DMT clinic without the scheduling constraints that make psilocybin-assisted therapy so operationally demanding and expensive. This is not a trivial difference; it is potentially the difference between a treatment available only to the wealthy and one that can scale to population need.

Pharmacological Mechanism Differences

Psilocybin is a prodrug: it is converted to psilocin in the body, which then acts primarily at 5-HT2A receptors. DMT acts directly at 5-HT2A receptors (plus sigma-1 and trace amine receptors) without prodrug conversion, producing an extremely rapid onset. Ketamine works primarily through NMDA receptor antagonism, a glutamatergic mechanism distinct from serotonergic psychedelics. Ketamine produces dissociation and mild perceptual effects but not the full mystical-type experiences associated with serotonergic psychedelics. This distinction appears clinically relevant: the depth of mystical experience predicts antidepressant outcomes in psilocybin studies, and similar patterns are emerging in DMT research.

Experience Quality

DMT is generally considered to produce the most intense subjective psychedelic experience per unit of time of any known compound. The onset in intravenous administration can be virtually instantaneous, producing a complete departure from ordinary consciousness within seconds. This intensity is both a clinical asset (profound therapeutic experiences in a short window) and a potential challenge for vulnerable patients who may find the sudden onset overwhelming without adequate preparation.

Mechanism of Action: Neuroplasticity and the DMN

5-HT2A Agonism and BDNF

DMT's primary mechanism of antidepressant action is believed to involve 5-HT2A receptor agonism in the prefrontal cortex. Activation of 5-HT2A receptors initiates signalling cascades that upregulate BDNF (brain-derived neurotrophic factor), the key protein for neuroplasticity. BDNF promotes the growth of new synaptic connections, essentially restoring neural flexibility that depression suppresses. A 2021 study by Ly et al. in Cell Reports found that DMT at sub-hallucinogenic doses in rodents produced structural neural plasticity (increased spinogenesis and synaptogenesis) via TrkB receptor signalling, suggesting neuroplasticity effects that may be partially independent of the hallucinogenic experience itself.

Default Mode Network Disruption

Robin Carhart-Harris and colleagues at Imperial College London have made the default mode network (DMN) a central focus of psychedelic research. Their work, including the landmark 2012 paper in PNAS using psilocybin, demonstrated that psychedelics acutely disrupt the self-referential, ruminative DMN connectivity that is a hallmark of depressive states. DMT produces one of the most pronounced disruptions to DMN connectivity of any studied compound, correlating with the reports of ego dissolution and self-transcendence that characterise DMT experiences.

The Entropy Theory

Carhart-Harris has proposed that psychedelics increase "neural entropy," the informational complexity and randomness of brain activity, disrupting the overly constrained, stereotyped patterns of neural activity that depression and anxiety maintain. This entropy increase is visible on EEG as broadband power increases and on fMRI as increased functional connectivity between brain regions that are normally segregated. From this lens, DMT does not add a new chemical to the brain; it temporarily releases the brain's own regulatory constraints, allowing novel patterns to emerge.

The Sigma-1 Receptor

DMT is also a high-affinity agonist at the sigma-1 receptor (S1R), a chaperone protein involved in calcium signalling, neuroprotection, and neuroplasticity. S1R agonism has independently shown antidepressant-like and neuroprotective effects in animal models. DMT may be the only naturally occurring compound that simultaneously activates both 5-HT2A and S1R with high affinity, a unique pharmacological profile that may contribute to its distinctive effects.

Preliminary Efficacy Data

Small Pharma Phase 2a Results

Small Pharma's Phase 2a trial of SPL026 for MDD, published in 2024, involved adult participants with moderate-to-severe depression. Participants received a single IV DMT session (at one of several doses) combined with psychological support. The primary endpoint was change in MADRS scores at two weeks post-dosing. The trial reported significant antidepressant effects at the higher dose levels, with response rates (50% or greater reduction in MADRS) comparable to those seen in Phase 2 psilocybin trials. Remission rates were lower but still clinically meaningful.

Ayahuasca Efficacy Studies as Proxy Evidence

Because ayahuasca contains DMT as its primary psychoactive component, ayahuasca studies provide relevant proxy evidence for DMT's antidepressant potential. A 2018 randomised placebo-controlled trial by Palhano-Fontes et al. in Psychological Medicine found that a single ayahuasca session produced rapid and sustained antidepressant effects in treatment-resistant depression, with significant MADRS score reductions at 1 and 7 days. The effect size was comparable to ketamine. A 2019 open-label study by Osorio et al. found similar results, with 64% of participants showing antidepressant response and 36% achieving remission after a single session.

What the Data Does Not Yet Show

Current DMT efficacy data is primarily from small Phase 1 and Phase 2a trials, which are not adequately powered to establish efficacy definitively. Placebo control in psychedelic trials is methodologically challenging (it is difficult to blind participants to whether they received an active psychedelic). Long-term follow-up data beyond 2-3 months is limited. Comparative effectiveness against established treatments (SSRIs, CBT) has not been formally studied. All these gaps represent the normal status of early-phase drug development, not a reason to dismiss the early signals.

The Regulatory Pathway

FDA Breakthrough Therapy Designation

FDA Breakthrough Therapy designation is granted to drugs that may offer substantial improvement over available therapies for serious conditions. Psilocybin has received Breakthrough Therapy designation from the FDA twice (COMPASS Pathways for treatment-resistant depression in 2018, and Usona Institute for MDD in 2019). MDMA-assisted therapy received it in 2017. DMT-specific compounds had not received formal Breakthrough Therapy designation as of early 2026, though Small Pharma's clinical progress positions the compound favourably for future consideration.

The Australian Precedent

Australia's Therapeutic Goods Administration (TGA) made history in February 2023 by approving psilocybin and MDMA for use in psychedelic-assisted therapy under strictly controlled conditions. Authorised Prescribers can administer these treatments for treatment-resistant depression (psilocybin) and PTSD (MDMA) in approved clinical settings. This regulatory approval does not cover DMT, but it establishes the precedent and framework that DMT approval could follow in Australia and potentially other jurisdictions.

The US Regulatory Timeline

The FDA's rejection of MDMA-assisted therapy (Lykos Therapeutics' PTSD application) in August 2024 was a setback for the broader psychedelic medicine field, though the FDA's concerns were specific to trial design and data integrity rather than the fundamental principle of psychedelic-assisted therapy. The rejection refocused attention on the importance of methodological rigour and highlighted the need for larger, better-designed Phase 3 trials. For DMT, which is earlier in clinical development, this context underscores both the opportunity (substantial unmet need) and the challenge (regulatory bar is high and getting higher).

Safety Profile: Clinical vs Recreational

Clinical Safety Data

In clinical settings with medical screening and supervision, IV DMT's safety profile has been acceptable. Acute cardiovascular effects (elevated heart rate and blood pressure during the 15-30 minute active window) are the primary physiological concern and are monitored carefully. No serious adverse cardiovascular events were reported in Small Pharma's Phase 2a at the doses studied. Psychological challenges (acute anxiety, fear, confusion) were managed through psychological support protocols and were generally resolved within the session window.

Contraindications

Clinical DMT protocols exclude participants with personal or family history of psychosis or schizophrenia (5-HT2A agonists can trigger psychotic episodes in predisposed individuals), certain cardiac conditions, concurrent use of MAOIs (which can dramatically extend and intensify DMT effects), concurrent SSRI use (which may blunt effects and carries theoretical interaction risks), and active suicidal ideation with intent and plan. These exclusions are standard across psychedelic trial protocols.

Recreational DMT Risks

Outside clinical settings, DMT's risks increase substantially. Set and setting matter enormously with high-intensity psychedelics. Recreational use without preparation, screening, or support can produce acute psychological crises, including panic, dissociation, and persisting perception disorder (HPPD) in rare cases. DMT is not physiologically addictive (no physical withdrawal syndrome), but its psychological intensity creates potential for psychologically challenging experiences that are not therapeutic when uncontained. This context is precisely what clinical protocols are designed to manage.

The Ayahuasca Connection

The Chemistry of the Brew

Oral DMT is normally metabolised in the gut by monoamine oxidase A (MAO-A) before it reaches the brain. Traditional ayahuasca preparations solve this problem by combining DMT-containing plants with Banisteriopsis caapi vine, which contains beta-carboline alkaloids (harmine, harmaline, tetrahydroharmine) that inhibit MAO-A. This combination allows DMT to reach the brain orally, producing an experience lasting 4-6 hours with a different pharmacokinetic and phenomenological profile than intravenous DMT.

Ayahuasca Research

The most extensive clinical research with an oral DMT-containing preparation comes from studies in Brazil, where the União do Vegetal and Santo Daime churches use ayahuasca sacramentally and have been subjects of research. Jordi Riba at the Hospital de Sant Pau in Barcelona conducted foundational pharmacological and neuroimaging research with ayahuasca. The clinical depression studies by Palhano-Fontes, Osorio, and colleagues at the Federal University of Rio Grande do Norte represent the strongest clinical evidence base for DMT as an antidepressant, and this body of work directly informed Small Pharma's synthetic DMT programme.

Shamanic Ceremonial Use vs Clinical Synthetic DMT

The Different Containers

Shamanic ayahuasca ceremony and clinical DMT administration are profoundly different contexts for the same or related chemical experiences. Traditional ayahuasca ceremony is embedded in an Indigenous cosmology with specific songs (icaros), ritual purification, dietary restrictions (dieta), group setting, and a trained curandero who guides and interprets the experience. The container is communal, cosmologically situated, and transgenerational. Clinical DMT administration occurs in a medical setting with pre-session psychotherapy, a therapist monitoring physical safety, standardised dosing, and a structured integration process.

What Each Offers

Clinical contexts offer safety screening, standardised dosing, integration support, and accessibility for people who would not otherwise have access to traditional ceremony. They are appropriate for the medically vulnerable and are operating within legal frameworks. Traditional ceremony offers a cosmological framework that gives the experience meaning, a trained guide who has themselves undergone extensive training, and a communal context. Some researchers, including Gabor Mate (whose The Myth of Normal addresses psychedelic healing), argue that without meaningful ritual container, clinical efficiency may sacrifice some of the medicine's depth.

The Ethical Questions

As synthetic DMT enters mainstream medicine, questions arise about intellectual property, benefit-sharing, and acknowledgment of the indigenous traditions whose practices demonstrated the therapeutic potential of the compound. Several psychedelic medicine organisations have established ethical frameworks for this, including the Chacruna Institute for Psychedelic Plant Medicines. The pharmaceutical development of medicines derived from indigenous knowledge without corresponding benefit to those communities is a pattern with an uncomfortable historical track record.

Spiritual Experiences in Trials and Their Therapeutic Significance

Mystical Experience as a Predictor of Outcomes

Robin Carhart-Harris and colleagues published a landmark 2017 study in Lancet Psychiatry on psilocybin-assisted therapy for treatment-resistant depression. They found that the degree of mystical experience (measured with the validated Mystical Experience Questionnaire) was the single strongest predictor of antidepressant response, stronger than dose, patient demographics, or therapist variables. Similar findings have been reported from Johns Hopkins and NYU psilocybin studies. Early DMT research is generating consistent data: the patients who report the deepest experiences of unity, transcendence, and meaningfulness show the strongest antidepressant responses.

Entity Encounters and Their Interpretation

One of the most discussed aspects of DMT phenomenology is the consistent encounter with what participants describe as autonomous entities: beings, presences, or intelligences that seem real and independent. A 2020 survey by Davis et al. at Johns Hopkins, published in the Journal of Psychoactive Drugs, found that 45% of participants in a large online survey reported encounters with apparently sentient entities during DMT experiences, and the majority described these encounters as among the most meaningful experiences of their lives, with lasting positive effects on psychological wellbeing.

Researchers interpret these encounters in various ways: as projections of unconscious material, as aspects of the self rendered into experiential form, or as genuinely novel encounters with something the brain does not normally have access to. The scientific question of what these entities are remains entirely open. The clinical question of whether the encounters are therapeutically meaningful has a clearer answer: they appear to be.

Near-Death Experiences and the DMT Hypothesis

Strassman's original research documented that many participants described their DMT experiences as similar to or more intense than near-death experiences (NDEs). This observation, combined with the finding that endogenous DMT levels rise in rat brains at cardiac arrest (Dean et al., 2019), has generated the hypothesis that DMT may be involved in the NDE phenomenon. Pim van Lommel, a Dutch cardiologist and NDE researcher, has engaged with this hypothesis cautiously. The connection remains speculative but scientifically interesting; it points toward DMT's potential role in some of the most significant experiences human beings report.

Non-Psychedelic Consciousness Support from Thalira

For Those on Non-Psychedelic Paths

The research on DMT and other psychedelics demonstrates something important: the brain is capable of profound states of consciousness that are profoundly therapeutic. These states are not exclusive to psychedelic compounds. Deep meditation, breathwork, sensory deprivation, and certain mineral preparations have all been associated with expanded states of consciousness, though with different profiles and timescales.

ORMUS and Monatomic Minerals

ORMUS (Orbitally Rearranged Monatomic Elements), also called monatomic gold or white powder gold, refers to a class of mineral preparations theorised to exist in a high-spin, monatomic state that confers unusual properties. Clinical evidence for ORMUS is early and limited, but practitioners report enhanced clarity, coherence, and meditative depth. Thalira's ORMUS monatomic gold is used by many consciousness researchers and practitioners as a supporting tool for deepened states.

Meditation as a Non-Psychedelic Gateway

The research on experienced meditators documents that deep meditative states share neurological features with psychedelic states: reduced DMN activity, increased neural entropy, reports of unity consciousness and ego dissolution. These states are accessible without pharmacological agents, though they typically require years of dedicated practice to achieve reliably. The Thalira meditation tools collection supports this path with quality instruments for sustained practice.

The Future of Psychedelic Medicine

The Pipeline

As of early 2026, the psychedelic medicine pipeline is remarkably active. Beyond DMT, compounds in clinical development include psilocybin (multiple Phase 3 trials underway for depression, OCD, and smoking cessation), MDMA (Phase 3 for PTSD after the 2024 US regulatory setback, with ongoing trials in other jurisdictions), LSD (LSD-25 and analogues for anxiety), and ibogaine (addiction treatment, with particular interest in the VA and military veteran PTSD population). Each compound has a distinct pharmacological profile and potential therapeutic niche.

The Integration Challenge

Even if regulatory approval comes, the integration of psychedelic-assisted therapy into healthcare systems presents formidable challenges. Therapist training pipelines are years from matching projected demand. Insurance coverage remains limited. The requirement for extended therapy sessions raises cost and access barriers. And the cultural, institutional, and liability frameworks needed to support this kind of treatment do not yet exist at scale. The science is moving faster than the systems that would need to deliver it.

What DMT's Clinical Development Represents

DMT's progress through clinical trials represents more than a new drug in development. It represents the scientific system engaging, tentatively and rigorously, with a class of experiences that have been at the centre of human spiritual life across cultures for millennia. Whether the entities are real, whether consciousness extends beyond the brain, whether DMT accesses something genuinely numinous: these questions may never be settled by clinical trials. But the trials are documenting something real. People emerge from brief DMT sessions with lasting reductions in depression and lasting increases in a sense that life is meaningful. That is data worth taking seriously.